Alpha-gal syndrome (AGS), also known as alpha-gal allergy or mammalian meat allergy (MMA), is an acquired allergy to the epitope of the carbohydrate molecule galactose-alpha-1,3-galactose ("alpha-gal"). Reactions can be life-threatening, and typically either begin rapidly after exposure from intravenous therapy, or 2–8 hours after ingesting foods and medicines. Reactions can also occur from skin contact and environmental exposures. AGS results from tick bites, and possibly bites from other parasites. Alpha-gal is present in all foods and ingredients made from beef, pork, lamb, venison, rabbit, and other mammal sources, including gelatin and milk. Certain seaweeds also contain alpha-gal. Alpha-gal is found worldwide among the inactive ingredients and materials of medications and healthcare products, and it is generally not required to be labeled. Reactions have been reported from breathing cooking fumes containing alpha-gal molecules, and contact with health and personal care products. AGS patients may have a reaction near farm animals, and shoveling manure or other chores may require gloves or a respirator.
Signs and symptoms Reactions have been documented from intravenous medication, foods and medicines, skin contact, and environmental exposures. Allergic symptoms vary greatly between individuals and include rash, hives, nausea or vomiting, difficulty breathing, drop in blood pressure, dizziness, diarrhea, severe stomach pain, anaphylaxis, heart attack, and death.
Reactions to intravenous treatments Reactions to intravenous exposure, such as infusions and transfusions, are typically rapid. The cancer treatment cetuximab, gelatin-based plasma volume expanders, and certain antivenoms are forms of intravenous treatment that have been identified as particularly risky for patients with alpha-gal syndrome.
Reactions to foods and medicines
Reactions to alpha-gal in food or medicine typically have a delayed onset, beginning 2–8 hours after consumption. After the delayed onset, the allergic response is like most IgE-mediated food allergies, including severe whole-body itching, hives, angioedema, gastrointestinal upset, and possible anaphylaxis. Anaphylactic reactions are seen in approximately 60% of afflicted individuals. Some cases feature gastrointestinal symptoms without pruritus, hives, or other skin involvement. This presentation is not typical of food allergies, which can make the initial suspicion of alpha-gal syndrome less likely. It can lead to misdiagnosis of irritable bowel syndrome. American guidelines published in 2023 recommended physicians suspect alpha-gal syndrome in cases with abdominal pain and GI symptoms, but without traditional allergy symptoms like hives. In 70% of cases, the reaction is accompanied by respiratory distress and is particularly harmful to those with asthma. The severity of reaction to alpha-gal has been found to correlate with the amount of alpha-gal in the ingested food or drug. However, for many patients, not every exposure to alpha-gal results in an allergic reaction. Symptoms and sensitivity to reactions vary greatly among individuals. Other factors, including exercise and alcohol consumption, can affect an individual's symptoms and reactivity to alpha-gal.
Prevalence Alpha-gal allergy has been reported in 30 countries on all six continents where humans are bitten by ticks, particularly the United States and Australia. Prevalence can be correlated to populations of tick species that have been documented as carriers, such as the Lone Star tick (Amblyomma americanum) in the US and the paralysis tick (Ixodes holocyclus) in Australia. Alpha-gal has also been shown to exist in the saliva of Ixodes scapularis but not Amblyomma maculatum.
Availability of prevalence data In the United States, data on AGS prevalence is limited because positive blood test results and clinical diagnoses are not required to be reported in federal public health statistics. AGS is only a mandatory reportable condition for statistics in some US states. In September 2023, Arkansas became the first US state to make alpha-gal syndrome a reportable condition. As of June 2026, thirteen states track positive tests.
Australia In November 2019, Australia had the highest rate of alpha-gal syndrome and tick paralysis worldwide.
United States From 2010 to the end of 2022, over 100,000 cases of AGS were diagnosed by a laboratory in the United States. The Centers for Disease Control and Prevention's national estimate of cases totaled 450,000 at that time. The CDC report indicated that those numbers were likely an underestimate because AGS is neither nationally "reportable" nor mandated as reportable in all states, and also because many medical providers remain unfamiliar with AGS. In a 2010–2018 study, more than 34,000 suspected cases of AGS were identified. After that period, the annual number of positive test results increased from 13,371 in 2017 to 18,885 in 2021. Virginia reported 14,000 positive cases from September 2025 to June 2026, ten times its rate of Lyme disease. In the US, AGS is more prevalent in the central and southern regions, which corresponds to the distribution of the lone star tick. In the Southern United States, where the tick is most prevalent, allergy rates are 32% higher than elsewhere. 2012 research identified unexpectedly high rates of alpha-gal syndrome in certain western and north-central areas of the US. This suggests that another tick species may spread the allergy. The study also found alpha-gal syndrome cases in Hawaii, where no ticks associated with AGS are found.
Prognosis Alpha-gal syndrome is a long-term condition for which there is no cure. AGS can be fatal. AGS disproportionately affects people in their 40s and 50s when the human body begins to lose cardiac resilience. 30–40% of AGS patients have cardiac symptoms during reactions. Management typically requires ongoing access to a medical provider and avoidance of the alpha-gal molecule epitope. Symptoms may lessen or resolve over time for some AGS patients. For some people, the allergy improves after avoiding further tick bites over a time period from 8 months to 5 years.
… excerpt ends here. Continue reading the full article.




![Alpha-gal syndrome: Allergic sensitization to α-Gal.[65]](https://upload.wikimedia.org/wikipedia/commons/thumb/e/e3/Falgy-02-783279-g004.jpg/500px-Falgy-02-783279-g004.jpg?utm_source=en.wikipedia.org&utm_campaign=parser&utm_content=thumbnail)
